Compare DK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DK | GPCR |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2017 | 2023 |
| Metric | DK | GPCR |
|---|---|---|
| Price | $72.25 | $47.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $39.94 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 1.3M | 540.7K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 95.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.85 | $18.49 |
| 52 Week High | $72.00 | $94.90 |
| Indicator | DK | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 39.65 |
| Support Level | $58.20 | $46.40 |
| Resistance Level | N/A | $56.63 |
| Average True Range (ATR) | 3.92 | 2.23 |
| MACD | 0.19 | -0.66 |
| Stochastic Oscillator | 88.72 | 0.99 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment and retail segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.